Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > COLUMN
COLUMN
- Rewarding Value and Innovation and Ensuring Financial Viability of the Biopharmaceutical Supply Chain in Japan
March 16, 2023
- Why Market Mapping Is Critical to Your Organization
February 24, 2023
- When It Comes to Recruitment, Time Is Money. Have a Plan!
January 31, 2023
- Cell Therapy in Japan: A Potentially Attractive Market at a Turning Point Facing Challenges
December 16, 2022
- How to Succeed in Bad Times and Good
December 9, 2022
- The Pros and Cons of Working from Home in 2022
November 25, 2022
- Rare Diseases in Japan: Moving from Treatment to Integrated Care
October 27, 2022
- The Evolving US Managed Care Environment and Implications of US Market Attractiveness for Japanese Manufacturers
September 5, 2022
- Fairness, Not Diversity
August 26, 2022
- Healthcare Collaboration between Governments and Biopharma: Key Success Factors for Life Science Manufacturers and Future Implications
August 5, 2022
- The Winning Combination: Drive, Passion, and Commitment
July 22, 2022
- Please Come Back to the Office!
June 24, 2022
- Customer Engagement in the COVID-Endemic New Normal
June 17, 2022
- Tapping into One’s Ikigai by Working from Home
May 27, 2022
- The Road to Success Is Paved with the Stepping-Stones of Disappointment
April 22, 2022
- Five Ways to Get Your New Hire on the Same Page
March 31, 2022
- 4 Things You Can Do to Overcome Zoom Overload
November 26, 2021
- What Does a Great Boss Look Like?
October 29, 2021
- What Is the Price of a Work-Life Balance?
September 24, 2021
- Obituary: P. Reed Maurer
September 14, 2021
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…